Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark is seeking European Union approval for its proposed $40 billion acquisition of Kenvue, adding a regulatory hurdle to a major consumer-healthcare transaction. The setup now turns on the EU review and whether the deal can combine Kenvue’s higher gross margins with Kimberly-Clark’s larger revenue base without diluting execution.
Kimberly-Clark has sought approval from the European Union for its proposed $40 billion acquisition of Kenvue, according to Investing.com. The filing places the transaction before another competition authority as the companies work through the regulatory process. No further details on the EU’s timetable, any concessions under discussion, or the precise areas of overlap were provided in the report.
The deal would combine Kimberly-Clark, whose reported fiscal-year revenue was $16.4 billion, with Kenvue, which reported $15.1 billion. Both companies posted a 2.1% year-over-year revenue decline in their latest reported fiscal years, so the transaction arrives against a backdrop of contraction rather than accelerating top-line growth. Kimberly-Clark reported $6.07 in diluted EPS, while Kenvue reported $0.76.
The financial profiles are different. Kimberly-Clark reported a 36.0% gross margin and a 12.3% net margin, compared with Kenvue’s 58.1% gross margin and 9.7% net margin. That gives the transaction exposure to Kenvue’s higher gross-margin portfolio, while also bringing together businesses with different cost structures and operating priorities.
For Kimberly-Clark, the immediate mechanism is regulatory clearance for a transaction that would materially expand its consumer-products footprint. For Kenvue, the EU filing is part of the process for a change in ownership and does not by itself establish that the deal will close.
The key uncertainty is therefore procedural as well as financial. The absence of those details limits the read-through to either company’s valuation and leaves the economics of the proposed combination untested in the available reporting.
Next, the relevant milestones are the European Commission’s response and any subsequent request for concessions, followed by the broader regulatory and shareholder approvals required to complete the deal. Investors will also need the companies to disclose the transaction’s financing, expected synergies, closing conditions, and pro forma earnings impact. Until those details arrive, the EU filing advances the process but does not settle the ultimate financial effect on Kimberly-Clark or Kenvue.
The EU filing advances KMB’s $40 billion Kenvue transaction, but without terms or a regulatory timetable the evidence leaves both KMB and KVUE in a process-driven, two-sided setup.
KMB’s larger revenue base and KVUE’s 58.1% gross margin show a potentially complementary combination, while both companies’ latest reported revenue declined 2.1% year over year and the pro forma earnings effect is unknown.
A formal EU objection, required divestitures, a delayed review, or unfavorable financing and synergy terms would weaken the transaction case; approval without meaningful synergies would also limit the upside.
CoverageSource: Investing.com · Published here FRI, AUG 28 · 12:32 PM ET · the only report in this recordHow this is decided →
STOCK PHOTO · RACHEL CLAIREEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
KMB could gain exposure to KVUE’s 58.1% gross margin and combine businesses with reported revenues of $16.4 billion and $15.1 billion, creating a larger consumer-products platform.
The only grounded countercase in the available reporting is execution and regulatory uncertainty: both companies reported revenue declines of 2.1% year over year, while no synergies, financing terms, or EU remedies have been disclosed.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →